关键词：非黑色素瘤皮肤癌；基底细胞；鳞状细胞癌
摘 要：Non-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which starts in the squamous cells. BCC usually develops in the areas such as the head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of the hands. These can also grow in wounds or chronic skin sores. Non-melanoma skin cancer is caused by unprotected and excessive exposure to UV radiation. It affects men more than women. It can be cured effectively if it is detected early. Treatment for non-melanoma skin cancer includes surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and PDT.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Global Non-melanoma Skin Cancer Drugs

Market

06.3.1 Market Size and Forecast

06.4 Global Actinic Keratosis Drugs Market

06.4.1 Market Overview

06.4.2 Market Size and Forecast

06.5 Top Selling Drugs for the Treatment of BCC, SCC,

and Actinic Keratosis

06.6 Five Forces Analysis

07. Market Segmentation by Type

07.1 Global Non-melanoma Skin Cancer Drugs

Market by Type

07.1.1 BCC

07.1.2 SCC

07.2 Global BCC Drugs Market

07.2.1 Market Size and Forecast

07.3 Global SCC Drugs Market

07.3.1 Market Size and Forecast

08. Pipeline Analysis

09. Geographical Segmentation

09.1 Global Non-melanoma Skin Cancer Market by

Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

17.1 Market Share Analysis 2013

17.2 Global Actinic Keratosis Drugs Market

17.3 Other Prominent Vendors

18. Non-invasive Treatment Market

18.1 Global Non-melanoma Skin Cancer

Radiotherapy Market

18.1.1 Market Size and Forecast

18.2 Global Non-melanoma Skin Cancer

Cryotherapy Market

18.2.1 Market Size and Forecast

18.3 Global Non-melanoma Skin Cancer PDT Market

18.3.1 Market Size and Forecast

18.4 Global Non-melanoma Skin Cancer Laser

Therapy Market

18.4.1 Market Size and Forecast

18.5 Vendor Share

18.5.1 Global Non-melanoma Skin Cancer Radiotherapy

Equipment Market

18.5.2 Global Non-melanoma Skin Cancer Cryotherapy

Equipment Market.

18.5.3 Global Non-melanoma Skin Cancer PDT Equipment

Market

18.5.4 Global Non-melanoma Skin Cancer Laser Equipment

Market

19. Key Vendor Analysis

19.1 Elekta AB

19.1.1 Key Facts

19.1.2 Business Description

19.1.3 Product Categorization

19.1.4 Revenue by Product Offerings

19.1.5 Revenue Comparison by Geographical Segmentation

2012 and 2013

19.1.6 Revenue Comparison by Geographical Segmentation

19.1.7 Business Strategy

19.1.8 Key Developments

19.1.9 SWOT Analysis

19.1.10 Strengths

19.1.11 Weaknesses

19.1.12 Opportunities

19.1.13 Threats

19.2 F. Hoffmann-La Roche Ltd.

19.2.1 Key Facts

19.2.2 Business Description

19.2.3 Business Segmentation

19.2.4 Revenue by Business Segmentation

19.2.5 Geographical Sales Segmentation by Business Segments

19.2.6 Business Strategy

19.2.7 Key Information

19.2.8 SWOT Analysis

19.2.9 Strengths

19.2.10 Weaknesses

19.2.11 Opportunities

19.2.12 Threats

19.3 iCAD Inc.

19.3.1 Key Facts

19.3.2 Business Description

19.3.3 Business Segmentation

19.3.4 Revenue by Business Segmentation

19.3.5 Revenue Comparison by Business Segmentation 2012

and 2013

19.3.6 Revenue by Geographical Segmentation

19.3.7 Business Strategy

19.3.8 Key Developments

19.3.9 SWOT Analysis

19.3.10 Strengths

19.3.11 Weaknesses

19.3.12 Opportunities

19.3.13 Threats

19.4 Meda AB

19.4.1 Key Facts

19.4.2 Business Description

19.4.3 Product Segmentation

19.4.4 Revenue by Product Segmentation

19.4.5 Revenue Comparison by Product Segmentation 2012

and 2013

19.4.6 Revenue by Geographical Segmentation

19.4.7 Business Strategy

19.4.8 Key Developments

19.4.9 SWOT Analysis

19.4.10 Strengths

19.4.11 Weaknesses

19.4.12 Opportunities

19.4.13 Threats

19.5 Valeant Pharmaceuticals International Inc.

19.5.1 Key Facts

19.5.2 Business Description

19.5.3 Business Segmentation

19.5.4 Revenue Comparison by Business Segmentation 2011-

2013

19.5.5 Revenue by Geographical Segmentation

19.5.6 Business Strategy

19.5.7 Key Developments

19.5.8 SWOT Analysis

19.5.9 Strengths

19.5.10 Weaknesses

19.5.11 Opportunities

19.5.12 Threats

19.6 Varian Medical Systems Inc.

19.6.1 Key Facts

19.6.2 Business Description

19.6.3 Business Segmentation

19.6.4 Revenue by Business Segmentation

19.6.5 Revenue Comparison by Business Segmentation 2013

and 2012

19.6.6 Revenue by Geographical Segmentation

19.6.7 Business Strategy

19.6.8 Key Developments

19.6.9 SWOT Analysis

19.6.10 Strengths

19.6.11 Weaknesses

19.6.12 Opportunities

19.6.13 Threats

20. Other Reports in this Series